Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders.
Lead Product(s): Deferasirox
Therapeutic Area: Hematology Product Name: DST-0509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2021